Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
Consequently, further studies are required to clarify these possible connections
it is a powerful medication that directly impacts your endocrine system
After 48 hours of incubation, a fixed dose of Arsenic Trioxide was added and 48 hours later cell viability was measured by the MTT method
These findings indicate Day 30 of liver organoids as the optimal stage for drug metabolism and toxicological investigations, providing a proteomic framework that enhances their utility of iHLOs as physiologically relevant liver models